Corcept Therapeutics reported $100.39M in Gross Profit on Sales for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
TG Therapeutics TGTX:US USD 92K 479K
Acadia Pharmaceuticals ACAD:US USD 128.58M 3.32M
Ani Pharmaceuticals ANIP:US USD 50.93M 12.37M
Aurora Cannabis Inc ACB:CN CAD -22824000 580K
Biomarin Pharmaceutical BMRN:US USD 389.06M 21.62M
Bristol Myers Squibb BMY:US USD 8.86B 345M
Canopy Growth Corp WEED:CN CAD 3.82M 5.21M
Corcept Therapeutics CORT:US USD 100.39M 1.68M
Eli Lilly And LLY:US USD 5.36B 305M
Esperion Therapeutics ESPR:US USD 12.47M 2.81M
Johnson & Johnson JNJ:US USD 15.94B 56M
Knight Therapeutics Inc GUD:CN CAD 30.4M 7.89M
Lannett LCI:US USD 12.6M 4.74M
Merk MRK:US USD 11.52B 1.08B
Nektar Therapeutics NKTR:US USD 18.65M 2.18M
Novartis NOVN:VX USD 9.18B 151M
Novartis NVS:US USD 9.18B 151M
Pacira Pharmaceuticals PCRX:US USD 116.79M 2M
Pfizer PFE:US USD 16.55B 2.52B